Healthcare
Live Price
Offline$5.67
-0.87% today
1Y Change
+131.43%
Window
Jun 23, 2025 → Jun 17, 2026
Coverage: 248 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Verano Holdings Corp. (VRNO) is a Healthcare stock with a market cap of $460.00M and listed on OTC. The stock last traded around $5.67 and up 131.4% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of -4.9%, EPS growth of +24.2%, a dividend yield of 0.0%. What stands out right now is revenue -4.9%, EPS +24.2%, free cash flow -10.0% with operating margin 9.4% and ROIC 4.8%. Valuation is more restrained than many high-expectation growth names at price/sales 0.6. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines VRNO price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VRNO
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
VRNO Max Drawdown
-54.07%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for VRNO and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$731.4M
-16.8% YoY
FY Net Income
-$57.5M
+78.6% YoY
Free Cash Flow
$51.4M
+307.1% YoY
Revenue Growth
-4.9%
EPS Growth
+24.2%
Gross Margin
49.4%
Net Margin
-32.6%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 836M | 879M | 938M | 879M | 731M |
| Gross Profit | 429M | 444M | 475M | 423M | 320M |
| Operating Income | 95M | -237M | 85M | -161M | 60M |
| EBITDA | 222M | -94M | 239M | 36M | 170M |
| Net Income | -262M | -342M | -117M | -269M | -58M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 83M | 88M | 175M | 85M | 99M |
| Total Assets | 1.8B | 2.0B | 2.3B | 2.4B | 2.5B |
| Total Liabilities | 1.1B | 1.0B | 1.1B | 1.1B | 1.1B |
| Shareholder Equity | 703M | 952M | 1.2B | 1.3B | 1.5B |
| Total Debt | 502M | 523M | 543M | 499M | 353M |
| Net Debt | 419M | 435M | 368M | 414M | 254M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
191M
+102.9% YoY
Capital Expenditures
140M
-17.5% YoY
Free Cash Flow
51M
+307.1% YoY
Key ratios
Gross Margin
49.4%
Operating Margin
9.4%
Net Margin
-32.6%
ROE
-33.2%
Debt / Equity
0.72x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.